Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound probiotics plus triple therapy vs bismuth-based quadruple therapy for Helicobacter pylori eradication (non-inferiority)
ChiCTR2200058491Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Shenzhen Hospital
- Start
- Mar 2022
- Modality
- Small Molecules, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of probiotic complex and omeprazole + amoxicillin + clarithromycin in Helicobacter pylori infection (2 arms), sponsored by Southern Medical University Shenzhen Hospital. Primary endpoint: H. pylori eradication rate. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
probiotic complexomeprazole + amoxicillin + clarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200058491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058491.